Interleukin-2 receptor antagonist therapy leads to increased tacrolimus levels after kidney transplantation

Therapeutic Drug Monitoring

Volumn 37, Issue 2, 2015, Pages 206-213

  Lin, Sonia ^a   Henning, Alice K ^b   Akhlaghi, Fatemeh ^c   Reisfield, Robin ^d   Vergara Silva, Andrea ^e   First, M Roy ^d  

^a UNIVERSITY OF COLORADO HOSPITAL   (United States)

^b EMMES CORPORATION   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^e Ziopharm Oncology Inc   (United States)

Author keywords

calcineurin inhibitors; corticosteroids; drug drug interaction; interleukin 2 receptor antagonists; pharmacokinetics

Indexed keywords

BASILIXIMAB; CREATININE; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR; LYMPHOCYTE ANTIBODY;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG MONITORING; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; KIDNEY TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; GRAFT SURVIVAL; MIDDLE AGED; RABBIT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SURVIVAL RATE; TIME;

ADULT; ANIMALS; ANTILYMPHOCYTE SERUM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; GLUCOCORTICOIDS; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RABBITS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, INTERLEUKIN-2; RETROSPECTIVE STUDIES; SURVIVAL RATE; TACROLIMUS; TIME FACTORS;

EID: 84925882777     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000125     Document Type: Article

References (23)

1. Meier-Kriesche HU, Li S, Gruessner RWG, et al. Immunosuppression: evolution of practice and trends, 1994-2004. Am J Transplant. 2006;6(pt 2): 1111-1131.
2. Srinivas TR, Meier-Kriesche HU, Kaplan B. Pharmacokinetic principles of immunosuppressive drugs. Am J Transplant. 2005;5:207-217.
3. Christians U, Jacobsen W, Benet LZ, et al. Mechanisms of clinical relevant drug interactions associated with tacrolimus. Clin Pharmacokinet. 2002;41:813-815.
4. Van Gelder T. Drug interactions with tacrolimus. Drug Saf. 2002;25: 707-712.
5. Ciacci C, Mahida YR, Dignass A, et al. Functional inerleukin-2 receptors on intestinal epithelial cells. J Clin Invest. 1993;92:527-532.
6. Abdel-Razzak Z, Loyer P, Fautrel A, et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepato-cytes in primary culture. Mol Pharmacol. 1993;44:707-715.
7. Tinel M, Robin MA, Doostzadeh J, et al. The interleukin-2 receptor down-regulated the expression of cytochrome P450 in cultured rat hep-atocytes. Gastroenterology. 1995;109:1589-1599.
8. Boggi U, Danesi R, Vistoli F, et al. A benefit-risk assessment of basilix-imab in renal transplantation. Drug Saf. 2004;27:91-106.
9. Simulect Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2005.
10. Strehlau J, Pape L, Offner G, et al. Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. Lancet. 2000;356:1327-1328.
11. Ganschow R, Grabhorn E, Burdelski M. Basiliximab in paediatric liver-transplant recipients [Correspondence]. Lancet. 2001;357:388-389.
12. Sifontis NM, Benedetti E, Vasquez EM. Clinical significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. Transpl Proc. 2002;34:1730-1732.
13. Vester U, Kranz B, Treichel U, et al. Basiliximab in paediatric liver-transplant recipients [Correspondence]. Lancet. 2001;357:388-389.
14. Woodle ES, First MR, Pirsch J, et al; the Astellas Corticosteroid Withdrawal Study Group. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008; 248:564-577.
15. Lam S, Partovi N, Ting LS, et al. Corticosteroid interactions with cyclo-sporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction? Ann Pharmacother. 2008;42:1037-1047.
16. Anglicheau D, Flamant M, Schlageter MH, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant. 2003;18:2409-2414.
17. Duijnhoven EM, Boots JMM, Chistiaans MHL, et al. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int. 2003;16; 721-725.
18. Hesselink DA, Ngyuen H, Wabbijn M, et al. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. Br J Clin Pharmacol. 2003;56: 327-330.
19. Scott LJ, McKeage K, Kean SJ, et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs. 2003;63: 1247-1297.
20. Zahir H, McLachlan AJ, Nelson A, et al. Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. Ther Drug Monit. 2005;27:422-430.
21. Undre NA, Schafer A. Factors affecting the pharmacokinetics of tacro-limus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. Transplant Proc. 1998;30:1261-1263.
22. Anglicheau D, Legendre C, Thervet E. Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives. Transplantation. 2004;78:311-315.
23. Dirks NH, Huth B, Yates CR, et al. Pharmacokinetics of immunosup-pressants: a perspective on ethnic differences. Int J Clin Pharmacol Ther. 2001;42:701-718.